Skip to main content
Premium Trial:

Request an Annual Quote

Twelve RNAi-Related Patent Applications Published by the USPTO, August 2005

Premium

Title: Small Interfering RNA-Mediated Heritable Gene Manipulation in Plants

Number: 20050166289

Filed: Dec. 1, 2004

Lead Inventor: Vincent Lee Chuan Chiang, North Carolina State University

According to the patent application's abstract, the invention comprises "methods and compositions for stably modulating gene expression in plants, [as well as] … plants and cells comprising the compositions of the presently disclosed subject matter."


Title: Enhancement of RNAi Activity Through Mutation

Number: 20050166272

Filed: Dec. 8, 2004

Lead Inventor: Kazunari Taira, National Institute of Advanced Industrial Science and Technology

According to the patent application's abstract, the invention is "a double-stranded RNA comprising an antisense RNA and a sense RNA with specific mutations [and] having enhanced RNAi activities. The double stranded RNA has at least one substitution or insertion mutation introduced at a first, second or third nucleotide position from the 5' end of the antisense RNA or at 17-19 position as counted from the 3' end of the antisense sequence excluding an overhang, and the antisense RNA is complementary to a region of an mRNA of a target gene except the at least one substitution or insertion mutation. Related single-strand RNAs, vectors, methods, cells and compositions are disclosed," the abstract states.


Title: Methods for Treating Prostate Cancer Using siRNA Duplex for Androgen Receptor

Number: 20050164970

Filed: Dec. 22, 2004

Lead Inventor: Benyi Li, University of Kansas Medical Center

The patent application covers "interfering RNA duplexes directed to the androgen receptor associated with prostate cancer," its abstract states. "A method of treating prostate cancer using interfering RNA duplexes to mediate gene silencing is also provided."


Title: RNA Interference-Mediated Inhibition of ADAM33 Gene Expression Using Short Interfering Nucleic Acid

Number: 20050164968

Filed: Aug. 10, 2004

Lead Inventor: James McSwiggen, Sirna Therapeutics

According to the patent application's abstract, the invention "relates to compounds, compositions, and methods useful for modulating ADAM33 gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of ADAM33 gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of ADAM33 genes."


Title: RNA Interference-Mediated Inhibition of Platelet-Derived Endothelial Cell Growth Factor (ECGF1) Gene Expression Using Short Interfering Nucleic Acid

Number: 20050164967

Filed: Aug. 19, 2004

Lead Inventor: James McSwiggen, Sirna Therapeutics

The patent application, its abstract states, "relates to compounds, compositions, and methods useful for modulating platelet-derived endothelial cell growth factor and/or receptor (ECGF1 and/or ECGF1r) gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of ECGF1 and/or ECGF1r gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of ECGF1 and/or ECGF1r genes."


Title: RNA Interference-Mediated Inhibition of Type I Insulin-Like Growth Factor Receptor Gene Expression Using Short Interfering Nucleic Acid

Number: 20050164966

Filed: Aug. 16, 2004

Lead Inventor: James McSwiggen, Sirna Therapeutics

The invention "relates to compounds, compositions, and methods useful for modulating type I insulin-like growth factor receptor gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of type I insulin-like growth factor receptor gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of type 1 insulin-like growth factor receptor genes."


Title: Methods and Means for Producing [an] Efficient Silencing Construct Using Recombinational Cloning

Number: 20050164394

Filed: Jan. 13, 2005

Lead Inventor: Christopher Helliwell, Commonwealth Scientific and Industrial Research Organization

The patent application, its abstract states, covers "methods and means … for producing chimeric nucleic acid constructs capable of producing dsRNA for silencing target nucleic acid sequences of interest using recombinational cloning."


Title: Modified iRNA Agents

Number: 20050164235

Filed: Sept. 21, 2004

Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals

"The invention," the patent application's abstract states, "relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a carbohydrate; or a steroid, e.g., cholesterol, which is optionally substituted with at least one carbohydrate. is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents," the abstract adds.


Title: RNA Interference-Mediated Inhibition of Cyclin D1 Gene Expression Using Short Interfering Nucleic Acid

Number: 20050164224

Filed: July 16, 2004

Lead Inventor: James McSwiggen, Sirna Therapeutics

"This invention relates to compounds, compositions, and methods useful for modulating cyclin (e.g., cyclin D1) and/or cyclin dependent kinase (CDK) gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of cyclin and/or cyclin dependent kinase gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of cyclin and/or cyclin dependent kinase genes."


Title: Modulation of Gene Expression Using DNA-RNA Hybrids

Number: 20050164212

Filed: March 4, 2004

Lead Inventor: Todd Hauser, OligoEngine

The "invention is directed to novel DNA-RNA hybrids comprising either a DNA sense strand and an RNA antisense strand, or an RNA sense strand and a DNA antisense strand," the patent application's abstract states. "The compounds of the invention, and compositions and arrays comprising the same, may be used for a variety of purposes, including inhibiting gene expression, treating disease and infection, determining the function of genes, and identifying and validating novel drugs and their targets."


Title: Modulation of HSV Infection

Number: 20050164172

Filed: Jan. 21, 2005

Lead Inventor: Evelyn Kurt-Jones, University of Massachusetts Medical School

"Toll-like receptor 2 (TLR2) has been found to mediate certain effects of HSV infection, particularly in neonates," the patent application's abstract states. "Compounds [including siRNAs] that decrease TLR2 expression or activity are useful for ameliorating such deleterious effects."


Title: Controlled and Sustained Delivery of Nucleic Acid-Based Therapeutic Agents

Number: 20050163844

Filed: Jan. 26, 2005

Inventor: Paul Ashton, Control Delivery Systems

"The invention provides insertable drug delivery devices for the controlled and sustained release of nucleic acid-based therapeutic agents, including antisense agents, siRNAs, ribozymes, and aptamers," the patent application's abstract states.

 

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.